All You Need to Know About Checkpoint Inhibitors

October 1, 2018

Since the approval of the first PD-1 checkpoint inhibitor, Keytruda, in 2014, there has been an explosion of the numbers of trials testing these drugs, both alone and in combination. The latest figure, coming from the Cancer Research Institute (CRI) in the US, sets the number in over 1,500 trials.

Spotlight

Evercyte GmbH

Evercyte will establish the new concept of “pharmacocellomicsTM” in the field of pre-clinical developments. Therefore, we will provide primary cells from different patients and tissues that are immortalized by telomerase or other strategies (SV40; SNEV) that we have established. Thus we guarantee cell strains with the most similar phenotype to the primary cells in sufficient amounts to perform reproducible preclinical drug testing. We will deliver (i) single immortalized cell strains including mesenchymal stem cells that can be differentiated to the cell type of interest; (ii) cell panels including sufficient cell strains of different tissues and/or donors of different status (healthy, diseased, young, old, etc) in order to generate statistically meaningful data that allow to estimate drug efficiencies and toxicity with high predictive power.

Other Infographics
news image

Global Bioinformatics Market

Infographic | August 23, 2021

As per the study, the global Bioinformatics market was valued at $3.4 billion in 2013, and it is expected to reach $12.8 billion by 2020. The market is expected to grow at a CAGR of 21.2% during 2014-2020

Read More
news image

The COVID-19 pandemic has swept the globe, yet many people still do not understand how it affects the body

Infographic | April 16, 2020

The COVID-19 pandemic has swept the globe, yet many people still do not understand how it affects the body. This infographic shows the events that occur following SARS-CoV-2 infection

Read More
news image

Building the European biotech sector with world-class science and innovation

Infographic | August 5, 2021

Europe continues to be a powerhouse of science and innovation. The region maintains a clear lead over China, the United States, and the rest of the world in terms of the quality and quantity of its science. For example, Europe is home to 43 of the global top 100 life-science universities, while the United States has 34. Europe is a powerhouse in scientific publishing as well, with roughly twice the output of the United States and three times that of China.Europe also leads in terms of quality, as measured by the number of citations for its publications. More than 40,000 biotech patents have been granted in Europe since 2015, although the region’s 3 percent CAGR in patent approvals between 2015 and 2019 lagged behind that of the United States (4 percent) and was a fraction of China’s (14 percent).Despite Europe’s strength in science and innovation, translation remains the biggest challenge. Translation of science into companies is stagnant. The distribution of newly funded biotechs remains unchanged across geographies over the last six years, and Europe accounts for only 25 percent of new biotechs. Future success will depend on improving the translation of research into new companies, raising more capital, and building entrepreneurial talent.

Read More
news image

What Paraspeckles Can Teach Us About Basic Cell Biology

Infographic | December 1, 2019

Discovering a new type of subnuclear body taught me how pursuing the unexpected can lead to new insights—in this case, about long noncoding RNAs and liquid-liquid phase separation in cells.

Read More
news image

Merck’s 23 CRISPR Patents Leading the way in genome-editing technology

Infographic | April 7, 2020

CRISPR Integration: CRISPR/Cas9 System for insertion in eukaryotic cells Compositions and use of CRISPR/Cas9 to integrate a new sequence of DNA after cutting genomic DNA. CRISPR-chrom: Improves access to the genome so that CRISPR-driven edits can be done more efficiently.

Read More
news image

Designing Genetic Circuit

Infographic | April 13, 2020

Near the turn of the millennium, James Collins and Stanislas Leibler independently undertook rather similar projects: design what would become synthetic biology’s seminal genetic circuits. And they came up with strikingly similar action plans—use E. coli to pair promoters with repressors that control one another’s behavior.

Read More

Spotlight

Evercyte GmbH

Evercyte will establish the new concept of “pharmacocellomicsTM” in the field of pre-clinical developments. Therefore, we will provide primary cells from different patients and tissues that are immortalized by telomerase or other strategies (SV40; SNEV) that we have established. Thus we guarantee cell strains with the most similar phenotype to the primary cells in sufficient amounts to perform reproducible preclinical drug testing. We will deliver (i) single immortalized cell strains including mesenchymal stem cells that can be differentiated to the cell type of interest; (ii) cell panels including sufficient cell strains of different tissues and/or donors of different status (healthy, diseased, young, old, etc) in order to generate statistically meaningful data that allow to estimate drug efficiencies and toxicity with high predictive power.

Events